Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hypertension II: Pathophysiology

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Hypertension and Regulation of Blood Pressure

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Action of β1 Blockers

Antihypertensive Drugs: Action of β₁ Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chediak-Higashi Syndrome With Epstein-Barr Virus Triggered Hemophagocytic Lymphohistiocytosis: A Case Report.

Cureus·2020

Same author

Basic and clinical aspects of bradykinin receptor antagonists.

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques·2014

Same author

The kallikrein-kinin pathways in hypertension and diabetes.

Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques·2014

Same author

Hypertension and the bradykinin system.

Current hypertension reports·2009

Same author

Cardiovascular activities of the bradykinin system.

TheScientificWorldJournal·2008

Same author

Role of tissue kallikrein-kininogen-kinin pathways in the cardiovascular system.

Archives of medical research·2006

Search research articles

Related Experiment Video

Updated: May 22, 2026

Assessing Murine Resistance Artery Function Using Pressure Myography

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

The kinin system in hypertensive pathophysiology.

Jagdish N Sharma¹

¹Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Health Sciences Center, Kuwait University, P.O. Box 24923, 13110, Safat, Kuwait. j.n.sharma@hsc.edu.kw

Inflammopharmacology

|April 25, 2012

Summary

This summary is machine-generated.

The kallikrein-kinin system plays a key role in cardiovascular health. Reduced activity of this system is linked to cardiovascular diseases, but enhancing it shows therapeutic promise.

More Related Videos

Imaging Leukocyte Adhesion to the Vascular Endothelium at High Intraluminal Pressure

Imaging Leukocyte Adhesion to the Vascular Endothelium at High Intraluminal Pressure

Published on: August 23, 2011

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Related Experiment Videos

Last Updated: May 22, 2026

Assessing Murine Resistance Artery Function Using Pressure Myography

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

Imaging Leukocyte Adhesion to the Vascular Endothelium at High Intraluminal Pressure

Imaging Leukocyte Adhesion to the Vascular Endothelium at High Intraluminal Pressure

Published on: August 23, 2011

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Area of Science:

Cardiovascular Physiology and Pharmacology
Molecular Medicine

Background:

Cardiovascular diseases (CVDs) are the leading global cause of mortality.
The kallikrein-kinin system (KKS) is implicated in vascular smooth muscle and cardiac function.
Reduced KKS activity is associated with various cardiovascular conditions including hypertension, ischemia, and hypertrophy.

Purpose of the Study:

To explore the role of the kallikrein-kinin system in cardiovascular pathophysiology.
To investigate the therapeutic potential of modulating the KKS for cardiovascular and renal diseases.

Main Methods:

Review of clinical and experimental data linking KKS activity to disease states.
Analysis of the mechanisms underlying the cardioprotective effects of angiotensin-converting enzyme inhibitors.
Evaluation of kallikrein gene delivery and kinin agonists as potential therapies.

Main Results:

Evidence suggests reduced KKS activity contributes to cardiovascular disease development.
Angiotensin-converting enzyme inhibitors' benefits are partly mediated by preserving kinin-forming components.
Kallikrein gene delivery demonstrates a broad range of beneficial effects.

Conclusions:

Restoring or enhancing kallikrein-kinin system activity holds significant therapeutic potential for hypertension, cardiovascular, and renal diseases.
Kallikrein gene therapy and future kinin agonists represent promising strategies for managing these conditions.